Study of sacituzumab tirumotecan plus pembrolizumab for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cervical cancer called squamous cell, adenosquamous, or adenocarcinoma.
- Your cancer has spread to other parts of the body (stage IVB) or has come back after treatment and cannot be cured with surgery or radiation.
- Your tumor has a protein called PD-L1, measured as a combined positive score (CPS) of 1 or higher.
- You are in reasonably good health, able to care for yourself (ECOG score 0 or 1).
- You have not had other cancer treatments for this stage of cervical cancer beyond what is allowed in this study.
- You do not have certain other serious medical conditions, like active autoimmune disease, severe dry eye syndrome, or inflammatory bowel disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs before standard treatment for locally advanced cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
This clinical trial tests a combination of two drugs—Sac-TMT (an antibody-drug conjugate that targets tumor cells) and bevacizumab (a drug that blocks blood vessel growth to tumors)—as a second-line treatment for advanced non-squamous non-small cell lung cancer. The goal is to see if this combination can help people whose cancer has progressed after initial chemotherapy and immunotherapy.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.